FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
Fixed-duration subcutaneous mosunetuzumab shows favorable efficacy and safety versus IV in relapsed follicular lymphoma
Subcutaneous Mosunetuzumab Shows Promise for Follicular Lymphoma Patients
This Phase 2 primary analysis evaluated fixed-duration subcutaneous mosunetuzumab versus mosunetuzumab IV in patients with relapsed or refra…
A Phase 2 trial found subcutaneous mosunetuzumab had lower rates of severe side effects than the IV version for treating follicular lymphoma…
Abexinostat showed a 69.5% objective response rate in relapsed follicular lymphoma patients
New Drug Shrinks Stubborn Lymphoma Tumors After Other Treatments Fail
This single-arm, multi-center phase 2 study evaluated abexinostat in 90 patients with relapsed or refractory follicular lymphoma who had rec…
A new treatment is helping some patients with stubborn lymphoma shrink tumors and stay in control for over a year, even after other therapie…
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma
Can adding a drug cocktail to radiation help keep early lymphoma from returning?
In a multicenter RCT with 150 patients with early-stage follicular lymphoma and 11.3-year median follow-up, involved-field radiotherapy plus…
Adding R-CVP drugs to radiation therapy helps early-stage lymphoma patients stay cancer-free longer, with mostly temporary side effects and …
Research across Non-Hodgkin's Lymphoma
Related studies from across the Non-Hodgkin's Lymphoma family.
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis
Zanubrutinib shows high response rates in diffuse large B-cell lymphoma patients
A meta-analysis of 1,346 patients with diffuse large B-cell lymphoma shows zanubrutinib achieves high response rates and prolonged survival.…
Zanubrutinib helped 95 out of 100 previously untreated patients with diffuse large B-cell lymphoma respond to treatment in this analysis.
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma
New immunotherapy options offer high response rates for Diffuse Large B-Cell Lymphoma patients
This narrative review surveys immunotherapy options for diffuse large B-cell lymphoma beyond rituximab, including bispecific antibodies, CAR…
New immunotherapy treatments show high response rates for Diffuse Large B-Cell Lymphoma, offering hope beyond the standard 60% success rate …
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus
CAR-T Trials Show Promise But Face Big Hurdles For Lymphoma Patients
This systematic landscape review of 360 CAR-T cell therapy trials for non-Hodgkin lymphoma found rapid expansion with a predominant focus on…
New research shows that CAR-T cell trials are expanding quickly but scientists must solve big problems like drug resistance before patients …
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
FDA approves new drug Xpovio for certain blood cancers.
The FDA approved Xpovio (selinexor) for multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, …
The FDA approved Xpovio (selinexor) for multiple myeloma and a type of lymphoma called DLBCL. It offers a new option for patients who have t…
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
New cancer therapies double response rates for tough lymphoma
This systematic review and meta-analysis of phase 1-2 trials evaluated experimental agents alone or combined with CD20-antibodies in adults …
Patients with aggressive lymphoma once had few options after standard treatments failed, but new therapies are changing that outlook in ways…
Mecapegfilgrastim reduces grade 3+ neutropenia in treatment-naive diffuse large B-cell lymphoma patients versus no prophylaxis
New Drug Cuts Severe Infection Risk In Lymphoma Care
This randomized controlled trial evaluated mecapegfilgrastim in 42 treatment-naive patients with diffuse large B-cell lymphoma.
A new long-acting injection lowers the risk of dangerous low white blood cell counts in lymphoma patients starting their first round of chem…
Case report documents HIV-associated diffuse large B-cell lymphoma regression with cART
1. HEADLINE
This case report and literature review describes a 66-year-old male with stage IV HIV-associated diffuse large B-cell lymphoma.
HIV Treatment Clears Advanced Lymphoma Without Chemo
Questions about Follicular Lymphoma
What are the safety results for fixed-duration subcutaneous mosunetuzumab in Follicular Lymphoma?
Fixed-duration subcutaneous mosunetuzumab shows a favorable safety profile with lower rates of severe immune-related adverse events compared to the intravenous version in relapsed follicular lymphoma.
Full answer →Does adding R-CVP after radiotherapy improve survival for early-stage Follicular Lymphoma?
Adding R-CVP after radiotherapy significantly improves progression-free survival in early-stage follicular lymphoma, but overall survival benefit is not yet proven.
Full answer →Do new therapies help Follicular Lymphoma patients who progress within 24 months?
Yes, new therapies like CAR T cells, bispecific antibodies, and targeted drugs show high response rates in follicular lymphoma patients who progress within 24 months.
Full answer →What is the response rate for abexinostat in relapsed Follicular Lymphoma?
Abexinostat shows a 69.5% objective response rate in relapsed follicular lymphoma, based on a phase 2 trial.
Full answer →Can Revlimid be used to treat Follicular Lymphoma?
Yes, Revlimid (lenalidomide) is FDA-approved for previously treated follicular lymphoma, specifically in combination with rituximab.
Full answer →